secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001140361-25-003266
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants priority review to Insmed's brensocatib NDA for bronchiectasis; PDUFA Aug 12, 2025
--------------------------------------------------------------------------------

- FDA accepted NDA with Priority Review; target action date August 12, 2025 under PDUFA.
- Brensocatib would be first approved treatment for bronchiectasis and first DPP1 inhibitor if approved.
- NDA based on Phase 3 ASPEN study meeting primary endpoint of reduced annualized pulmonary exacerbation rate.
- Both 10 mg and 25 mg doses also met key secondary endpoints including time to first exacerbation.
- Insmed plans EU, UK, Japan submissions in 2025; commercial launches anticipated in 2026, pending approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/0001140361-25-003266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-003266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer